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Background: We examined the sizes of lymph nodes and metastatic foci
within the lymph nodes that affect false-positive and false-negative
lymph node staging by positron emission tomography in lung cancer.
Methods: Preoperative positron emission tomography and computed tomog-
raphy scans were performed for 564 lymph node stations in 80 patients with
peripheral-type lung cancer. The sizes of both the lymph nodes and the
metastatic foci within the lymph nodes were measured, and these measure-
ments were compared with those obtained with positron emission tomogra-
phy scanning. To establish general sizes of metastatic foci within the lymph
nodes, 277 metastatic lymph nodes in operative specimens previously resected
from another 111 patients with lung cancer were examined as a control.
Results: The sensitivity was significantly higher for positron emission tomography than
for computed tomographic scanning (P  .026). The sizes of metastatic foci within
lymph nodes that showed false-negative (n 8) and true-positive (n 28) with positron
emission tomography ranged from 0.5 to 9 mm (3  1 mm) and from 4 to 18 mm (10
 3 mm), respectively (P .001). None of the metastatic foci smaller than 4 mm could
be detected with positron emission tomography scanning. The review of the 277
previously resected metastatic lymph nodes showed that 89 (32%) had metastatic foci
smaller than 4 mm. The sizes of true-positive (n  28) and false-positive (n  10)
lymph nodes ranged from 6 to 15 mm (10 2 mm) and from 9 to 16 mm (12 2 mm),
respectively (P .01). None of the false-positive lymph nodes was smaller than 9 mm.
Conclusions: Although positron emission tomography was superior to computed
tomography scanning in lymph node staging in lung cancer, positron emission
tomography was unable to distinguish metastatic foci smaller than 4 mm, which
were not unusual sizes for lymph node metastases in lung cancer. Positive lymph
nodes with positron emission tomography smaller than 9 mm are likely to be
true-positive rather than false-positive.
Several diagnostic procedures are used for preoperative staging ofpatients with lung cancer, including computed tomography (CT),magnetic resonance imaging, positron emission tomography (PET),mediastinoscopy, and thoracoscopy. Of the noninvasive procedures,CT remains the standard procedure for N staging in lung cancer.However, CT scanning is not sufficiently sensitive or specific for
diagnosing lymph node metastasis1; because size is the only criterion used to
differentiate benign from malignant lymph nodes, lymph nodes 1 cm or larger are
considered abnormal.
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In recent years, fluorodeoxyglucose (FDG)-PET scan-
ning has been used for the staging of lung cancer.2-7 Be-
cause of the biological nature of FDG, FDG-PET has been
reported to detect metastatic lymph nodes smaller than 1
cm. A meta-analysis by Dwamena and colleagues1 of PET
scanning of 514 patients in 14 studies showed that the mean
sensitivity and specificity for PET scanning in N staging
were 0.79 (range, 0.62 to 0.97) and 0.91 (range, 0.79 to
0.99), respectively, both of which were superior to those for
CT scanning, ie, 0.60 (range, 0.25 to 0.89) and 0.77 (range,
0.44 to 0.95), respectively. The detection of small metastatic
lymph nodes is, however, limited by the spatial resolution of
the PET scanner. In this study, to determine the lower size
limit of the metastatic lymph nodes that can be detected by
PET scanning, we measured the sizes of metastatic foci in
lymph nodes with true-positive (TP) and false-negative
(FN) results, and these results were compared with the sizes
of metastatic lymph nodes from another large series of lung
cancer patients to determine the general frequency of sizes
of metastatic lymph nodes. We also measured the sizes of
TP and false-positive (FP) lymph nodes to determine the
lymph node sizes that gave FP results on PET scan.
Materials and Methods
Subjects
Between December 2001 and May 2003, 85 patients with lung
cancer prospectively underwent FDG-PET and CT scanning be-
fore pulmonary resection with mediastinal lymph node dissection.
Lung cancer was peripheral type in 80 patients and central type in
5. For this study, we excluded the 5 patients with central-type lung
cancer, giving a total of 564 lymph node stations in the 80 patients
with peripheral-type lung cancer who were evaluated. The histo-
logic type of lung cancer was adenocarcinoma in 57 patients,
squamous cell carcinoma in 14, large cell carcinoma in 3, small
cell carcinoma in 3, carcinosarcoma in 2, and adenosquamous
carcinoma in 1 (Table 1). The pathologic N stages were N0 in 56,
N1 in 10, N2 in 11, and N3 in 3. The lymph nodes were classified
according to the original lymph node map of lung cancer.8 All
patients underwent thoracotomy without mediastinoscopy, except
for 3 patients with N3 disease. The 3 patients with N3 disease had
primary tumors in the left lung, which were resected with con-
tralateral lymph node dissection by median sternotomy.
FDG-PET Scanning
Patients were instructed to fast for at least 4 hours before intrave-
nous administration of FDG. The administered dosage of FDG was
125 Ci/kg (4.6 MBq/kg) of body weight for nondiabetic patients
and 150 Ci/kg (5.6 MBq/kg) of body weight for diabetic patients.
PET imaging was performed approximately 60 minutes after in-
travenous administration of the FDG by using a POSICAM.HZL
m-POWER (Positron Co, Houston, Tex). No-attenuation-corrected
emission scans were initially obtained in 2-dimensional, high-
sensitivity mode for 4 minutes per bed position and taken from the
vertical skull through to the mid thighs. Immediately thereafter, a
2-bed-position attenuation-corrected examination was performed,
with 6 minutes for the emission sequence and 6 minutes for the
transmission sequence at each bed position. The images were
usually reconstructed in a 256  256 matrix by using ordered
subset expectation maximization corresponding to a pixel size of 4
 4 mm, with section spacing of 2.66 mm.
N Staging by PET Scanning
PET data were evaluated semiquantitatively on the basis of the
contrast ratio (CR), which was obtained as follows. The regions of
interest (ROIs) were placed in the lymph nodes and cerebellum.
The highest activities in both the lymph node ROI (L) and the
cerebellum ROI (C) were measured. The CR was calculated by
L/C in each lymph node as an index of FDG uptake. Receiver
operating characteristic curves9 were constructed according to the
CR value and pathologic diagnosis, and the cutoff value was
determined for diagnosis of metastasis.
N Staging by CT Scanning
Spiral CT was performed by using the ProSeed SA (General
Electric Medical Systems, Milwaukee, Wis). The following acqui-
sition parameters were used: high voltage (120 kV), tube load of
160 mA, window level of 500 Hounsfield units (HU), and
window width of 1500 HU. The entire thorax was scanned with
1-cm-thick sections at 1 breath hold with maximum inspiration.
The criterion of CT definition for suspected metastasis of the
lymph node was a short-axis diameter of 1.0 cm or larger.
TABLE 1. Characteristics of patients with peripheral lung
cancer who underwent positron emission tomography and
computed tomography
Variable Data
Age (y) 65 12
Sex
Male 57
Female 23
Tumor size (cm) 3.3 2.0
Tumor location
Right upper lobe 27
Right middle lobe 5
Right lower lobe 10
Left upper lobe 21
Left lower lobe 17
Histology
Adenocarcinoma 57
Squamous cell carcinoma 14
Large cell carcinoma 3
Small cell carcinoma 3
Carcinosarcoma 2
Adenosquamous carcinoma 1
Pathologic N stage
N0 56
N1 10
N2 11
N3 3
Total 80
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Measuring the Size of Lymph Nodes
In each lymph node station that was TP or FP with PET scan, the
short-axis diameters of the largest lymph nodes were measured on
CT scan.
Measuring the Size of Metastasis
The dissected lymph nodes were examined histologically by using
formalin-fixed and paraffin-embedded sections with hematoxylin
and eosin staining. Each lymph node was examined with 1 hema-
toxylin and eosin–stained section. In each lymph node station
containing metastases, the lymph node with the largest metastatic
lesions was selected, and the long-axis diameters of the metastatic
foci in the lymph nodes were measured. The sizes of metastatic
foci were measured with a microscope.
Control Subjects
Another 277 metastatic lymph nodes from 111 patients with lung
cancer who had undergone operation with mediastinal lymph node
dissection from 1985 to 2001 were also examined as a control in
the same way: that is, (1) the lymph nodes with the largest
metastatic lesions in each lymph node station were selected, and
(2) the long-axis diameters of the metastatic foci were measured.
The sizes were classified in 1-mm graduations from the smaller-
than-1-mm class to the 10-mm-or-larger class. The histologic types
were adenocarcinoma in 72 patients, squamous cell carcinoma in
26, large cell carcinoma in 10, and adenosquamous carcinoma in 3
(Table 2). The pathologic classification was N1 in 36 patients, N2
in 69, and N3 in 6.
Statistical Analysis
TP, true-negative (TN), FP, and FN results of PET and CT scan-
ning for lymph node metastasis were compared with the results of
pathologic diagnosis. Sensitivity was calculated as TP/TP  FN,
specificity as TN/TN  FP, positive predictive value as TP/TP 
FP, negative predictive value as TN/TN FN, and accuracy as TP
 TN/total. All data were analyzed for significance by using the
2-tailed Student t test. All values in the text and tables are given as
mean  SD.
Results
The sensitivity and specificity in each CR value showed the
optimal CR cutoff value to be 0.25 (Figure 1). Therefore,
lymph nodes with a CR of 0.25 or higher were defined as
positive for FDG and those with CR less than 0.25 as
negative.
In the 564 lymph node stations examined, PET scanning
yielded TP in 28 lymph node stations, FN in 8, FP in 10, and
TN in 518 (Table 3). For the same lymph nodes, CT
scanning yielded TP in 19 lymph node stations, FN in 17,
FP in 8, and TN in 520 (Table 4). PET and CT scanning
showed a sensitivity of 78% and 53%, a specificity of 98%
and 98%, an accuracy of 97% and 96%, a positive predic-
tive value of 74% and 70%, and a negative predictive value
of 98% and 97%, respectively (Table 5). PET scanning
showed significantly higher sensitivity than CT scanning (P
 .026), although there were no significant differences in
specificity, accuracy, positive predictive value, or negative
predictive value between the 2 diagnostic modalities. In the
8 FN lymph nodes with PET, 5 were located in the hilar
lymph node station (#12), 1 in the interlobar station (#11),
1 in the tracheobronchial station (#4), and 1 in the Botallo
station (#5).
Table 6 shows the correlation between N staging with
PET and pathologic N staging. PET scanning correctly
identified the N stage in 67 patients, whereas it showed
understaging in 7 and overstaging in 6, of which the accu-
racy was 84%. Table 7 shows the correlation between N
staging with CT and pathologic N staging. CT scanning
correctly identified the N stages in 60 patients, whereas it
showed understaging in 14 patients and overstaging in 6, of
TABLE 2. Characteristics of control of lung cancers with
lymph node metastasis
Variable No.
Histology
Adenocarcinoma 72
Squamous cell carcinoma 26
Large cell carcinoma 10
Adenosquamous carcinoma 3
Pathologic N stage
N1 36
N2 69
N3 6
Total 111
Figure 1. Receiver operating characteristic curve and contrast
ratio (CR) value for diagnosing lymph node metastasis. The high-
est activities in the lymph node ROI (L) and in the cerebellum ROI
(C) were measured. The CR was calculated by L/C in each lymph
node station as an index of FDG uptake.
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which accuracy was 75%. There was no significant differ-
ence of accuracy in overall N staging between the PET and
CT scanning (P  .17). However, PET scanning could
identify 8 (73%) of 11 with N2 disease, which was signif-
icantly more accurate than 3 (27%) of 11 with CT (P 
.033). There was no significant difference of diagnosis for
N1 disease between the 2.
The sizes of the metastatic foci in the lymph nodes that
yielded FN results with PET scanning ranged from 0.5 to 9
mm, with a mean value of 3  1 mm, whereas those that
yielded TP results ranged from 4 to 18 mm, with a mean
value of 10  3 mm (Figure 2). There was a significant
difference in the size of metastatic foci between the FN and
TP lymph nodes (P  .001). PET scanning could detect
none of the metastatic foci smaller than 4 mm, but it could
detect all of the metastatic foci 5 mm or larger, except for 1
FN lymph node that had a metastatic lesion of carcinosar-
coma 9 mm in size. Metastasis in a single node was found
in 15 (54%) of the 28 TP lymph node stations and in 5
(50%) of 10 FN lymph node stations; the difference be-
tween the 2 was nonsignificant. None of the FN lymph
nodes had metastasis of bronchioloalveolar carcinoma,
which usually showed FN with PET scanning. The sizes of
the lymph nodes that yielded FP results on PET scanning
ranged from 9 to 16 mm, with a mean value of 12  2 mm,
whereas those that yielded TP results ranged from 6 to 15
mm, with a mean value of 10  2 mm (Figure 3). The
former was significantly larger than the latter (P  .01).
None of the FP lymph nodes was smaller than 9 mm. All of
the FP lymph nodes had histologic findings of reactive
lymph adenitis.
Table 8 shows the distribution in sizes of metastatic foci
in the 277 metastatic lymph nodes of the 111 patients in
Table 2. Eighty-nine lymph nodes (32%) had metastatic foci
smaller than 4 mm. Of the 111 patients, 34 (31%) had
metastatic foci smaller than 4 mm.
Discussion
Whereas a standard uptake value (SUV) is used for diag-
nosis of malignancy, we evaluated the activity ratio with CR
instead of SUV for the following reasons: (1) SUV is
dependent on the dose of FDG and the time of measurement
after injection of FDG, and (2) hyperglycemia in diabetic
patients decreases both the blood clearance of FDG and the
accumulation of FDG in tumor tissue. Actually, the mean
SUV of malignant pulmonary nodules has been report-
ed10-14 to range from 5.5 to 10.1. Several criteria have been
used to detect lymph node metastases of lung cancer by
using PET scanning, including accumulation of FDG with-
out objective criteria,6,15 accumulation greater than medias-
TABLE 3. Positron emission tomography analysis with
pathologic diagnosis
Variable
No. of lymph node stations
With metastasis Without metastasis Total
PET diagnosis
Positive 28 true-positive 10 false-positive 38
Negative 8 false-negative 518 true-negative 526
Total 36 528 564
PET, Positron emission tomography.
TABLE 4. Computed tomography analysis with pathologic
diagnosis
Variable
No. of lymph node stations
With metastasis Without metastasis Total
CT diagnosis
Positive 19 true-positive 8 false-positive 27
Negative 17 false-negative 520 true-negative 537
Total 36 528 564
CT, Computed tomography.
TABLE 5. Diagnostic results of PET and CT scanning
Variable PET CT Difference
Sensitivity 0.78 0.53 P  .026
Specificity 0.98 0.98 0.63
Accuracy 0.97 0.96 0.28
Positive predictive value 0.74 0.70 0.77
Negative predictive value 0.98 0.97 0.08
PET, Positron emission tomography; CT, computed tomography.
TABLE 6. Correlation of N staging with positron emission
tomography and pathologic N stage
PET diagnosis
Pathologic N stage
TotalN0 N1 N2 N3
N0 52 5 2 0 59
N1 3 4 0 0 7
N2 1 1 8 0 10
N3 0 0 1 3 4
Total 56 10 11 3 80
PET, Positron emission tomography.
TABLE 7. Correlation of N staging with computed tomog-
raphy and pathologic N stage
CT diagnosis
Pathologic N stage
TotalN0 N1 N2 N3
N0 52 7 6 0 65
N1 2 2 1 0 5
N2 2 1 3 0 6
N3 0 0 1 3 4
Total 56 10 11 3 80
CT, Computed tomography.
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tinal blood flow,2-4 and CR with the paravertebral mus-
cles.16 We evaluated the accumulation of FDG by using the
activity ratio in comparison to the cerebellum, because the
accumulation of FDG in the cerebellum is more stable than
that in mediastinal blood flow or in muscle. We found that
the cutoff value of 0.25 or larger was the most reliable for
diagnosing lymph node metastasis with PET scanning.
This study showed that the PET scan could not detect
lymph nodes that had metastatic foci smaller than 4 mm.
Because there was no significant difference of frequency of
single-node metastasis between the TP and FN lymph node
stations, the sensitivity of PET for N staging could be
dependent on the size of metastatic foci rather than on the
number of metastatic lymph nodes in each station. The FDG
uptake of small lesions may have been underestimated as a
result of the spatial resolution of the PET scanner, eg,
because of the partial-volume effect. Although Gupta and
colleagues3 reported that the sensitivity, specificity, and
accuracy of PET scanning for detecting lymph node metas-
tasis showed no difference between lymph nodes smaller
than 1 cm, 1 to 3 cm, or larger than 3 cm, they did not define
the lower size limit for PET scanning. To examine the
general distribution of general sizes of metastatic foci
within the lymph nodes, we measured the sizes of 277
metastatic lymph nodes in a large series of lung cancer
patients. If 4 mm were the lower limit for PET scanning to
detect metastatic foci, 89 (32%) of lymph nodes with me-
tastases smaller than 4 mm would yield FN results with PET
scanning. Even if 3 mm were the lower limit, 59 (21%) of
lymph nodes with metastases smaller than 3 mm would
yield FN results (Table 8). Considering the spatial resolu-
tion of the PET scanner, artifacts resulting from respiratory
movement, image reconstruction, and biological effects, it
is difficult to evaluate such small metastatic foci. Current
PET scanners, similar to the POSICAM used in this study,
achieve transaxial resolutions of 5 to 6 mm at full width,
half maximum. Tumors smaller than 10 mm could therefore
not be resolved even by the current scanner because of the
partial-volume effect. It has in fact been reported that the
current generation of PET scanners are unable to delineate
lung cancers smaller than 10 mm.17 This study did show,
however, that all metastatic foci 5 mm or larger, except 1
with the lesion 9 mm in size, were detected with PET
scanning, apparently exceeding the lower limit of spatial
resolution. We consider that metastatic foci smaller than 10
mm can be detected with PET scanning for the following
reasons: (1) metastatic tumor cells would have more bio-
logical activity than primary tumor cells, causing higher
FDG uptake in metastatic foci than in the primary sites, and
(2) the immune reaction of macrophages within metastatic
lymph nodes might increase FDG uptake, because FDG has
been reported to accumulate not only in tumor cells, but also
in macrophages.18
In this study, we excluded central-type lung cancer pa-
tients for the following reasons: (1) it is difficult for PET
scanning to distinguish the primary tumor from adjacent
nodal metastasis, and (2) bronchial obstruction by a central
tumor can lead to inflammation in the locoregional lymph
Figure 2. The distribution of sizes of metastatic foci in false-
negative and true-positive lymph nodes with PET scan.
Figure 3. The distribution of sizes of metastatic true-positive and
false-positive lymph nodes with PET scan.
TABLE 8. Distribution of sizes of metastatic foci in the 277
metastatic lymph nodes
Variable
Size (mm)
<1 <2 <3 <4 <5 <6 <7 <8 <9 <10 >10 Total
No. 14 32 59 89 110 125 138 151 167 190 87 277
% 5 12 21 32 40 45 50 55 60 69 31 100
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nodes, with subsequent FDG uptake. Nevertheless, 6 (75%)
of 8 FN lymph node stations with PET scanning were
located in the hilar region. Although there was no significant
difference of accuracy for overall N staging between PET
and CT scanning, PET could identify N2 disease more
accurately than CT. Vesselle and associates19 also reported
that, although PET scanning could correctly differentiate
N0 or N1 from N2 or N3 disease, it could not reliably
identify N1 disease, with only 6 of 21 cases identified. We
therefore believe that PET scanning is useful for determin-
ing an indication of operation or neoadjuvant therapy for N2
disease but that it is not reliable for N1 disease.
It has been reported that FP results for lymph nodes can
occur with PET scanning because of concurrent inflamma-
tory conditions or centrally located lung cancer.20 Although
this study excluded centrally located lung cancers, it is well
known that lymph nodes near the primary tumor could
become enlarged with an immune reaction, which could
become positive with PET scanning because of FDG uptake
by reactive macrophages, resulting in an FP result. This
study showed that the FP lymph nodes with PET scanning
were significantly larger than the TP ones and that none of
the FP lymph nodes was smaller than 9 mm. Therefore, we
consider that positive lymph nodes with PET scanning
smaller than 9 mm are more likely to be TP than FP.
Although PET scanning is superior to CT scanning for N
staging in lung cancer, it was unable to detect metastatic
foci smaller than 4 mm, which were not unusual sizes for
metastatic lymph nodes in lung cancer. Positive lymph
nodes with PET scanning that are smaller than 9 mm are
more likely to be TP than FP.
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